Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369333 | 1.00 | PPARA (0.37) | PPARAPPARGMAPK14NPC1HPGD | |
| SCHEMBL28688897 | 1.00 | PPARA (0.37) | PPARAPPARGMAPK14NPC1HPGD | |
| SCHEMBL29368299 | 0.88 | SMN1; SMN2 (0.35) | NPC1HPGDRAB9ASMN1; SMN2ABCB1 | |
| SCHEMBL22823743 | 0.88 | SMN1; SMN2 (0.35) | NPC1HPGDRAB9ASMN1; SMN2ABCB1 | |
| SCHEMBL28672381 | 0.88 | SMN1; SMN2 (0.35) | NPC1HPGDRAB9ASMN1; SMN2ABCB1 | |
| SCHEMBL22823736 | 0.81 | PTGER1 (0.40) | NPC1HPGDRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29368013 | 0.81 | PTGER1 (0.40) | NPC1HPGDRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL28673201 | 0.81 | PTGER1 (0.40) | NPC1HPGDRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL22823978 | 0.81 | TSHR (0.33) | PPARAPPARGSCN9A | |
| SCHEMBL29602246 | 0.81 | TSHR (0.33) | PPARAPPARGSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-12-08 | — | — | US | disclosed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020254559-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CACNB1, SMN1; SMN2 | PPARA 3710/4885PPARG 3395/4885MAPK14 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.